Cytek Biosciences, Inc.

CTKB

US23285D1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
6.27 ^USD	-1.72%		-1.57%	-31.25%

May. 08	Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	MT
May. 08	Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cytek Biosciences, Inc. Appoints Todd Garland as Chief Commercial Officer

April 28, 2022 at 08:00 am EDT

Cytek Biosciences, Inc. announced the appointment of Todd Garland as chief commercial officer, effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of the company.

Latest news about Cytek Biosciences, Inc.

Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M	May. 08	MT
Cytek Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	Mar. 20	MT
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance	Mar. 19	MT
Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics	Mar. 19	CI
Cytek Biosciences, Inc. Announces CFO Changes	Mar. 19	CI
Cytek Biosciences Unveils New Manufacturing Facility in Wuxi, China	Mar. 08	MT
Cytek Biosciences, Inc. Opens A New 50,000-Square-Foot Facility in Wuxi, China	Mar. 07	CI
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	Mar. 06	MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.	Mar. 01	CI
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024	Mar. 01	CI
Cytek Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : Cytek Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Cytek Biosciences Agrees to Flow Cytometry Collaboration With Centre for Genomic Regulation, Pompeu Fabra University	Jan. 18	MT
Cytek Biosciences, Inc. Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries	Jan. 17	CI
Cytek Seeks Merger and Acquisitions	Jan. 11	CI
Transcript : Cytek Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM	Jan. 11
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023	Jan. 08	CI
Cytek Biosciences Introduces the Cytek Orion? Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry	Dec. 21	CI
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9	Dec. 14	MT
Cytek Biosciences Insider Sold Shares Worth $120,600, According to a Recent SEC Filing	Nov. 21	MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating	Nov. 09	MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.	Nov. 07	CI
Cytek Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (CTKB) CYTEK BIOSCIENCES Posts Q3 Revenue $48M, vs. Street Est of $55.5M	Nov. 07	MT

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-04 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Cytek Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.27 USD

Average target price

10 USD

Spread / Average Target

+59.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYTEK BIOSCIENCES, INC.	-31.25%	823M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+7.87%	185B
INTUITIVE SURGICAL, INC.	+12.75%	135B
SIEMENS HEALTHINEERS AG	-1.37%	62.21B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.88%	51.01B
EDWARDS LIFESCIENCES CORPORATION	+11.59%	51.28B
AGILENT TECHNOLOGIES, INC.	+2.71%	41.85B
GE HEALTHCARE TECHNOLOGIES INC.	+4.90%	37.02B
RESMED, INC.	+23.75%	31.27B

Other Advanced Medical Equipment & Technology